Smith & Nephew (LON:SN - Get Free Report)'s stock had its "buy" rating reaffirmed by equities researchers at Jefferies Financial Group in a research note issued to investors on Wednesday,London Stock Exchange reports. They currently have a GBX 1,500 price objective on the stock. Jefferies Financial Group's target price indicates a potential upside of 33.69% from the company's current price.
SN has been the subject of several other reports. Shore Capital Group reaffirmed a "buy" rating and set a GBX 1,000 price objective on shares of Smith & Nephew in a report on Tuesday, July 21st. Royal Bank Of Canada reiterated a "sector perform" rating and set a GBX 1,350 target price on shares of Smith & Nephew in a research report on Monday, June 29th. Deutsche Bank Aktiengesellschaft reissued a "hold" rating and issued a GBX 1,400 target price on shares of Smith & Nephew in a report on Thursday, July 30th. UBS Group restated a "neutral" rating and issued a GBX 1,300 price target on shares of Smith & Nephew in a research report on Tuesday, May 5th. Finally, Citigroup downgraded Smith & Nephew to a "buy" rating in a research note on Friday, July 10th. Four analysts have rated the stock with a Buy rating and five have given a Hold rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of GBX 1,200.11.
Get Our Latest Stock Report on SN
Smith & Nephew Trading Down 6.3%
Shares of LON:SN traded down GBX 75 during trading on Wednesday, hitting GBX 1,122. 5,541,759 shares of the stock were exchanged, compared to its average volume of 343,671. The company has a 50-day simple moving average of GBX 1,136.07 and a two-hundred day simple moving average of GBX 1,194.74. The company has a market capitalization of £12.30 billion, a P/E ratio of 40.40, a PEG ratio of 0.46 and a beta of 0.69. The company has a debt-to-equity ratio of 62.90, a quick ratio of 0.84 and a current ratio of 2.57.
About Smith & Nephew
(
Get Free Report)
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Smith & Nephew, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew wasn't on the list.
While Smith & Nephew currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
